Project Updates
Vaxxas
Credit; Vaxxas
Location: Brisbane, Australia
Project type: Biomedical Manufacturing facility
Area: 5,500m² (60,000ft²)
Vaxxas opened a new biomedical manufacturing facility in Brisbane, Australia, in June 2023. The facility is designed to support the scale-up of Vaxxas’ needle-free vaccine technology platform named high-density microarray patch (HD-MAP) for late-stage clinical trials and commercial products.
Thermo Fisher Scientific
Credit; Thermo Fisher Scientific
Location: Lengnau, Switzerland
Project type: Biomanufacturing facility
Area: 1.5 million square feet
Thermo Fisher Scientific developed a new biologics manufacturing facility in Lengnau, in the Swiss canton of Bern, to improve its pharmaceutical services capacity and manufacturing capabilities to meet the growing demand for biologic therapies.
Biogen
Credit; PictureDesignSwiss/Shutterstck.com
Location: Luterbach, Solothurn, Switzerland
Project type: Biologics manufacturing facility
Investment: CHF1.5bn ($1.5bn)
Biogen has developed a biologics manufacturing facility in Luterbach near Solothurn, Switzerland. The state-of-the-art facility aims to meet the increasing demand for high-quality protein-based drugs or biologics that target severe neurodegenerative, haematological or autoimmune diseases.
